

Application No. 10/623,142
Amendment dated January 25, 2006


Docket No.: 01946/100B035-1JSD

AMENDMENTS TO THE CLAIMS

Please amend the claims so that they read as follows:

Claims 1-29 (Canceled).

30. (Currently Amended) The compound



~~and salts~~ or a salt thereof.

31. (Canceled)

32. (Previously Presented) A composition comprising

- a. an active agent; and
- b. the compound of claim 30.

33. (Previously Presented) A composition as defined in claim 32, wherein said active agent is selected from the group consisting of a pharmacologic agent and a therapeutic active agent.

34. (Previously Presented) A composition as defined in claim 32, wherein said active agent is selected from the group consisting of a biologically active agent and a chemically active agent.

Application No. 10/623,142
Amendment dated January 25, 2006

Docket No.: 01946/100B035-JSD

35. (Previously Presented) A composition as defined in claim 34, wherein said biologically active agent is selected from the group consisting of a peptide, a polysaccharide, a mucopolysaccharide, a carbohydrate, a lipid, a pesticide, and any combination thereof.

36. (Previously Presented) A composition as defined in claim 35, wherein said active agent comprises a peptide.

37. (Previously Presented) A composition as defined in claim 35, wherein said active agent comprises a polysaccharide.

38. (Previously Presented) A composition as defined in claim 35, wherein said active agent comprises a mixture of mucopolysaccharides.

39. (Previously Presented) A composition as defined in claim 34, wherein said biologically active agent is a hormone.

40. (Previously Presented) A composition as defined in claim 38, wherein said mixture of mucopolysaccharides comprises heparin.

41. (Previously Presented) A composition as defined in claim 34, wherein said biologically active agent is selected from the group consisting of human growth hormones; bovine growth hormones; growth hormone-releasing hormones; interferons; interleukin-I, interleukin-II, insulin; heparin, calcitonin; erythropoietin; atrial natriuretic factor; antigens; monoclonal antibodies; somatostatin; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin; promolyn sodium; vancomycin; desferrioxamine (DFO); parathyroid hormone, anti-microbials, or any combination thereof.

42. (Previously Presented) The composition of claim 41, wherein said biologically active agent comprises insulin.

Docket No.: 01946/100B035-JSD

Application No. 10/623,142
Amendment dated January 25, 2006

Docket No.: 01946/100B035-USJD

49. (Previously Presented) A dosage unit form according to claim 48, consisting of a tablet.
50. (Previously Presented) A dosage unit form according to claim 48, consisting of a capsule.
51. (Previously Presented) The dosage unit form of claim 47, wherein said active agent is selected from the group consisting of a biologically active agent and a chemically active agent.
52. (Previously Presented) The dosage unit form of claim 51, wherein said biologically active agent is selected from the group consisting of a peptide, a polysaccharide, a mucopolysaccharide, a carbohydrate, a lipid, a pesticide, and any combination thereof.
53. (Previously Presented) The dosage unit form of claim 52, wherein said active agent comprises a polysaccharide.
54. (Previously Presented) The dosage unit form of claim 52, wherein said active agent comprises a peptide.
55. (Previously Presented) The dosage unit form of claim 52, wherein said active agent comprises a mixture of mucopolysaccharides.
56. (Previously Presented) The dosage unit form of claim 55, wherein said mixture of mucopolysaccharides comprises heparin.
57. (Previously Presented) The dosage unit form of claim 51, wherein said biologically active agent is selected from the group consisting of human growth hormones; bovine growth hormones; growth hormone-releasing hormones; interferons; interleukin-I, interleukin-II; insulin; heparin, calcitonin; erythropoietin; atrial natriuretic factor; antigens; monoclonal antibodies; somatostatin; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin;

Application No. 10/623,142
Amendment dated January 25, 2006

Docket No.: 01946/100B035-LJSD

cromolyn sodium; vancomycin; desferrioxamine (DFO); parathyroid hormone, anti-microbials, or any combination thereof.

58. (Previously Presented) The dosage unit form of claim 57, wherein said heparin comprises low molecular weight heparin.

59. (Previously Presented) The dosage unit form of claim 57, wherein said biologically active agent comprises insulin.

60. (Previously Presented) The dosage unit form of claim 57, wherein said biologically active agent comprises parathyroid hormones.

61. (Previously Presented) The dosage unit form of claim 57, wherein said biologically active agent comprises calcitonin.

62. (Previously Presented) The dosage unit form of claim 57, wherein said biologically active agent comprises human growth hormone.

63. (Previously Presented) A method for preparing a composition, said method comprising mixing:

- a. at least one biologically active agent;
- b. at least one compound as defined in claim 30; and
- c. optionally a dosing vehicle.

64. (Previously Presented) A method as defined in claim 63, wherein said biologically active agent comprises a peptide.

65. (Previously Presented) A method as defined in claim 63, wherein said biologically active agent comprises polysaccharide.

{W:\01946\100b035\usc\00641231.DOC 00000000000000000000000000000000 }

Application No. 10/623,142
Amendment dated January 25, 2006

Docket No.: 01946/100B035 USD

66. (Previously Presented) A method as defined in claim 65, wherein said polysaccharide comprises a mixture of muco-polysaccharides.

67. (Previously Presented) The method of claim 63, wherein said biologically active agent is selected from the group consisting of human growth hormones; bovine growth hormones; growth hormone-releasing hormones; interferons; interleukin-I; interleukin-II; insulin; heparin; calcitonin; erythropoietin; atrial natriuretic factor; antigens; monoclonal antibodies; somatostatin; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin; cromolyn sodium; vancomycin; desferrioxamine (DFO); parathyroid hormone, anti-microbial, or any combination thereof.

68. (Previously Presented) A method for administering an active agent to an animal, said method comprising administering to said animal a composition as defined in claim 32.

69. (Previously Presented) A method for administering an active agent as defined in claim 68, wherein said administration is oral.

70. (Previously Presented) A method for administering an active agent as defined in claim 68, wherein said animal is a mammal.

71. (Previously Presented) A method for administering an active agent as defined in claim 70, wherein said mammal is a human.

72. (Previously Presented) A method for administering an active agent as defined in claim 68, wherein said composition is a solid.

73. (Previously Presented) A method for administering an active agent as defined in claim 72, wherein said composition is a tablet or capsule.

74. (Previously Presented) A method for administering an active agent to an animal, said method comprising administering orally to said animal a composition as defined in claim 36.

{\\V:\\01946\\100b035\\usc\\00641231.DOC [REDACTED]}

Application No. 10/623,142
Amendment dated January 25, 2006

Docket No.: 01946/100B035-USD

75. (Previously Presented) A method for administering an active agent to an animal, said method comprising administering orally to said animal a composition as defined in claim 38.

76. (Previously Presented) A method for administering an active agent to an animal, said method comprising administering orally to said animal a composition as defined in claim 40.

77. (Previously Presented) A method for administering an active agent to an animal, said method comprising administering orally to said animal a composition as defined in claim 42.

78. (Previously Presented) A method for administering an active agent to an animal, said method comprising administering orally to said animal a composition as defined in claim 43.

79. (Previously Presented) A method for administering an active agent to an animal, said method comprising administering orally to said animal a composition as defined in claim 44.

80. (Previously Presented) A method for administering an active agent to an animal, said method comprising administering orally to said animal a composition as defined in claim 45.

81. (Previously Presented) A method for administering an active agent to an animal, said method comprising administering orally to said animal a composition as defined in claim 46.